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Disease progression after initial surgical
intervention for Takayasu arteritis
Sung Wan Ham, MD, S. Ram Kumar, MD, Vincent L. Rowe, MD, and Fred A. Weaver, MD, MMM,
Los Angeles, Calif
Objective: This study was conducted to determine the incidence of disease progression and the need for subsequent
revascularization procedures in patients with Takayasu arteritis (TA).
Methods: From 1980 to 2009, all patients with TA who underwent an initial revascularization procedure for end-organ
ischemia were identified. The incidence of subsequent revascularization in another vascular bed or revision of the initial
procedure was determined.
Results: Forty patients (36 women; mean age, 35) underwent an initial revascularization procedure. Indications for the
initial procedure were hypertension in 20, renal dysfunction in 9, extremity ischemia in 6, and stroke/transient ischemic
attack in 5. The initial revascularization consisted of 60 bypass procedures and 4 endovascular interventions. During a
mean follow-up of 6.4 years, progression of TA in another vascular bed or stenosis/occlusion of the initial revascular-
ization procedure occurred in 16 patients (40%). Five patients with progression required one procedure, whereas 11
required two or more surgical interventions. Procedures required were renal in 12, cerebrovascular in 8, extremity in 8,
aortic reconstruction in 5, and mesenteric in 1. Postoperative/30-day morbidity was 14%, and one operative death
occurred. Actuarial survival was 94% at 1 year and 85% at 5 years after the remedial procedure.
Conclusions: TA progression is common in patients who require revascularization for end-organ ischemia. This finding
emphasizes the need for global lifelong vascular surveillance of all patients who undergo surgical intervention for TA. The
effect of steroid and immunosuppressive therapy on reducing reoperation requires further study. (J Vasc Surg 2011;54:
1345-51.)
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iTakayasu arteritis (TA) is a nonspecific granulomatous
inflammatory aortitis of unknown etiology that affects the
aorta and its major branches. This arteriopathy produces
stenotic, occlusive, and less commonly, aneurysmal degen-
eration in characteristic patterns and results in symptomatic
end-organ ischemia. Clinical manifestations of TA can in-
clude stroke, ocular ischemia, extremity ischemia, aortic
valve insufficiency, and aneurysm formation. TA also com-
monly involves the renal arteries, with symptomatic mani-
festation in the form of renovascular hypertension and
ischemic nephropathy. TA-induced renovascular hyperten-
sion is often refractory to medication, with subsequent
renal and cardiac dysfunction that leads to premature
death.1-3
The value of surgical treatment for the management of
the complications of TA and the positive effect on survival
has been recognized by a number of reports and corrobo-
rates our own experience during the past 30 years.4-6,7-12
However, data on disease progression and the need for
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doi:10.1016/j.jvs.2011.04.044eintervention over the lifetime of patients with TA is
imited. In this report, we review the incidence of disease
rogression and the need for subsequent reintervention in
atients surgically treated at our institution for TA.
ETHODS
Patient population. From 1980 to 2009, all patients
ith TAwho underwent an initial surgical revascularization
rocedure for end-organ ischemia at University of South-
rn California (USC) hospitals were identified. All patients
et diagnostic criteria for TA as outlined by the American
ollege of Rheumatology.13 Hospital records, imaging
tudies, and outpatient records were reviewed, with the
pproval of the USC Health Sciences Institutional Review
oard. Patients who underwent vascular procedures per-
ormed for TA at other institutions were not indexed, and
nitial procedures were based on those performed at our
nstitution.
Information collected included demographic data such
s race, age, sex, and clinical data, including comorbidities,
istory of vascular procedures, baseline blood pressure,
umber of antihypertensive medications, serum creatinine
oncentration, use of corticosteroids or immunosuppres-
ants (or both), erythrocyte sedimentation rate (ESR),
omputed tomography (CT)/magnetic resonance angiog-
aphy (MRA), and angiographic findings; all procedures
erformed at our institution, associated 30-day/in-hospital
orbidity and mortality, and late survival. Graft surveil-
ance was assessed by periodic duplex ultrasound (DUS)
maging, CT, angiography, or MRA. The extent of aortic
nvolvement for each patient was classified using the 1994
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which was based on the initial aortogram.14
Hypertension was defined as systolic blood pressure
(SBP)140 mmHg or diastolic blood pressure (DBP)90
mm Hg,15 or preoperative use of one or more antihyperten-
sive medications. Renal dysfunction was defined as a serum
creatinine concentration 1.5 mg/dL or a need for dialysis.
Indications for surgery included signs and symptoms of vas-
cular insufficiency to end organs and severe hypertension
refractory to medical therapy in patients with known renal
artery disease or aortic stenosis.
The primary outcome measure was to determine the
incidence of disease progression and need for subsequent
revascularization procedures after an initial index revascu-
larization. Disease progression was defined as the develop-
ment of symptomatic arterial stenosis/occlusion in a vascu-
lar bed other than that of the index revascularization.
Progression, manifested by restenosis/occlusion of the in-
dex vascular bed, was considered a recurrence of the disease
and was determined by the return of original symptoms or
abnormalities seen on surveillance imaging. Secondary end
points evaluated included 30-day/in-hospital morbidity
and mortality of surgical procedures performed for new or
recurrent disease as well as long-term survival. The Social
Security Death Index was used to investigate mortality for
patients lost to follow-up.
Imaging studies. All patients underwent aortography
before any surgical or endovascular intervention. Aortog-
raphy included the ascending aorta, aortic arch, and de-
scending aorta to evaluate thoracic aortic involvement of
disease as well as the abdominal aorta and selective visceral
branch catheterization, when indicated, to define the ex-
tent of disease. CT scans with intravenous contrast were
performed to clarify the longitudinal extent of aortic/
branch vessel involvement. This information was used
along with the intraoperative findings to create inflow
anastomoses in the least diseased arterial segment.
DUS imaging was routinely performed intraoperatively
to assess the technical proficiency of all reconstructions for
revascularization. Detected abnormalities of reconstruc-
tions were revised at the operating surgeon’s discretion.
Postoperative revascularization patency was assessed by
serial DUS imaging at 1 and 6 months and then annually
thereafter. CT angiography, MRA, or angiography was
used adjunctively as needed. Stenosis or occlusion detected
by noninvasive imaging was confirmed by angiography.
Surgical technique. The abdominal aorta was ex-
posed through a subcostal incision extended to the 12th rib
for retroperitoneal exposure. A left seventh interspace tho-
racoabdominal approach was reserved for patients with
concomitant thoracic aortic involvement that required re-
pair. A retroperitoneal exposure was used for unilateral
renal bypasses, whereas a midline transperitoneal approach
was taken for simultaneous bilateral renal revasculariza-
tions. When extensive branch disease was found, ex vivo
techniques were used. Operations were staged for bilateral
revascularizations requiring ex vivo reconstruction. Ne-
phrectomy was performed when vascular reconstruction tas not possible because of inflammatory involvement of
he entire renal artery or extension into the renal hilum.
The general operative technique included the use of
ypass/interposition grafts exclusively rather than patch
ngioplasty or endarterectomy. Graft inflow was usually
rovided by a nondiseased segment of aorta. In select cases
hen extensive aortic disease was present, splenic, hepatic,
r common iliac arteries were used for inflow, namely for
enal artery bypasses. Distal anastomoses were placed in
egments of the arterial tree free of visible disease. The
referred conduit for bypass was autogenous saphenous
ein. Prosthetic grafts were used for aortic reconstructions
nd some bypasses when no suitable vein was available.
Statistical analysis. Continuous variables were sum-
arized as mean  standard error of the mean (SEM) and
ompared using two-tailed t tests. Categoric variables were
xpressed as frequency and percentage. Actuarial survival
as estimated using Kaplan-Meier analysis. P  .05 was
onsidered statistically significant. Statistical analysis was
erformed using SPSS 17.0 software (SPSS Inc, Chicago,
ll).
ESULTS
Forty patients (90% women) with TA underwent 64
ndex vascular procedures for end-organ ischemia, which
ncluded 60 bypass procedures and 4 endovascular inter-
entions. Primary indications for surgery were hypertension
n 20, renal dysfunction in 9, extremity ischemia in 6, and
erebrovascular insufficiency in 5. Demographic data are
ummarized in Table I. Patients were a mean age of 35 
6.1 years at the time of intervention. Hispanic patients
omprised 63% of the cohort. Nine patients had undergone
ascular interventions for TA-associated occlusive disease at
ther hospitals, comprising 7 renal artery percutaneous
able I. Demographics and characteristics of patients
ith Takayasu arteritis (TA)
Characteristicsa
TA patients
(n  40)
Women 36 (90)
Age, years 35  2.5
Race
Hispanic 25 (63)
Asian 10 (25)
White 5 (12)
Hypertension 34 (85)
Renal insufficiencyb 6 (15)
Dialysis dependent 3 (8)
Coronary artery disease 2 (5)
Congestive heart failure 2 (5)
Prior revascularization for TA 9 (23)
Follow-up (years) 6.41  1.2
Median (range) 3.22 (0.03-30)
Categoric data are presented as number (%) and continuous data mean 
tandard error of the mean, or as indicated.
Defined as serum creatinine 1.5 mg/dL and does not include dialysis-
ependent patients; data were not available for 3 patients.ransluminal angioplasties, 3 aortorenal bypasses, 1 bilateral
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Volume 54, Number 5 Ham et al 1347carotid artery bypass, and 1 nephrectomy. All prior revas-
cularizations had failed.
Approximately half of the patients had diffuse aortic
involvement (type V) based on the initial aortogram (Fig
1). Sixteen patients (40%) were receiving long-term therapy
with corticosteroids or immunosuppressive or cytotoxic
medications, including methotrexate, azathioprine, leuko-
vorin, or infliximab. The preintervention ESR rate was
26.2  5.11 mm/h.
The index procedures are listed by anatomic location in
Table II. Of the 64 interventions, 40 were renal procedures,
which includedopen revascularizationusing aortorenal bypass
in 28 kidneys, 3 of which were ex vivo repairs. The splenic
artery was used to revascularize two of these kidneys and the
common hepatic artery was used in one because of extensive
inflammation of the abdominal aorta. Five primary nephrec-
tomies were required, of which three were performed during
contralateral revascularization, one before contralateral revas-
cularization, and one was the sole procedure. Four patients
underwent four renal percutaneous transluminal angioplasty
procedures as the primary treatment for TA-associated renal
artery stenosis and renovascular hypertension.
Twelve aortic reconstructive procedures were per-
formed primarily for thoracic/abdominal aortic stenosis
Fig 1. Disease extent of the 1994 Tokyo International C
the initial aortogram. Classification type did not change(atypical coarctation) or bilateral lower extremity claudica- Fion, including aortobiiliac–femoral bypass, aortoaortic by-
ass, and aortic interposition grafting. One patient with
neurysmal dilation of the ascending aorta, with subse-
uent severe aortic regurgitation, required replacement of
he ascending aorta and aortic valve.
Eight bypass procedures were required for cerebrovas-
ular insufficiency, which included aortocarotid bypass in
even, and femoral-axillary bypass in a patient with one
ertebral artery for cerebral perfusion. Four procedures
ere required for upper extremity claudication, including
eft common carotid–left subclavian artery bypass/transpo-
ition in three patients and left common carotid–brachial
rtery bypass in one.
Mean follow-up of the index operation was 6.4  1.2
ears. During the study period, 38% of patients were lost to
ollow-up. Before being lost to follow-up, patients received
eriodic surveillance imaging for a mean of 54 months.
verall, the disease progressed in 16 patients (40%), in-
luding 5 with disease detected in a previously asymptom-
tic vascular, 5 with restenosis/occlusion/aneurysm of the
riginal vascular bed, 1 with para-anastomotic pseudoan-
urysm formation, and 6 with both (Tables II and III).
All patients with TA progression in a different vascular
ed experienced new symptoms of end-organ ischemia.
ence Classification of Takayasu arteritis is determined by
y patients with disease progression.onferive patients required one procedure, whereas 11 required
o
o
t
subcl
he ind
ation
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gression. Symptoms recurred in all patients with graft ste-
nosis and occlusion. One patient presented with a ruptured
Table II. Index and remedial procedures for 40 patients
Index procedure by anatomic location n  64
Renal 40
Aortorenal bypass 25
Visceral–renal bypass 3
Ex vivo 3
Nephrectomy 5
PTA 4
Aortic reconstruction 12
Aortobiiliac/femoral bypass 7
Infrarenal aortic replacement 3
Thoracic aorta–infrarenal aortic bypass 1
Ascending aortic replacement/AVR 1
Cerebrovascular 8
Aortocarotid bypass 7
Femoral–axillary bypass 1
Extremity 4
LCC–LSA bypass/transposition 3
LCC–brachial artery bypass 1
AVR, Aortic valve replacement; LCC, left common carotid artery; LSA, left
Table III. Details of patients with recurrence or progressi
Pt Sex
Age
(years) Index procedure Medi
1 F 45 Aortorenal BYP CPP,
2 F 19 Aortorenal BYP None
3 F 33 Supraceliac aortoiliac,
aortorenal BYP
Pred
4 F 19 Supraceliac aortofemoral
BYP
None
5 F 50 Aortorenal BYP None
6 F 24 Femoral-axillary BYP MTX
7 F 31 Aortofemoral,
aortorenal BYP
None
8 F 13 Carotid-subclavian BYP None
9 F 29 Aortorenal BYP Predn
10 F 46 Renal/iliac angioplasty AZA,
11 F 23 Renal angioplasty None
12 F 59 Renal angioplasty MTX
13 F 15 Aortocarotid BYP None
14 F 15 Aortorenal BYP None
15 F 41 Aortobicarotid BYP None
16 F 51 Supraceliac aortoiliac
BYP
Pred
asc, Ascending AZA, azathioprine; BYP, bypass; CPP, cyclophosphamide M
aType of immunosuppressive or steroid therapy being taken at the time of t
bExtent of aortic involvement classified according to the 1994 Tokyo Internpara-anastomotic pseudoaneurysm 8 years after the initial speration. Graft stenosis of the initial revascularization
ccurred in eight patients, and graft occlusion occurred in
wo. Pathologic evaluation of specimens from two graft
Remedial procedure by anatomic location n  34
Renal 12
Aortorenal bypass 9
PTA  stent 3
Extremity 8
Lower extremity bypass 3
Patch angioplasty/revisions 2
PTA  stent of lower extremity bypass
graft
1
LCC–LSA artery bypass 2
Cerebrovascular 8
Aortocarotid bypass 5
Carotid–carotid bypass 1
Carotid endarterectomy 1
Femoral–axillary bypass 1
Aortic reconstruction 6
Ascending aortic replacement/AVR 2
Para-anastomotic aneurysm repair 1
Aortobiiliac–femoral bypass 2
Aortomesenteric bypass 1
avian artery; PTA, percutaneous transluminal angioplasty.
f Takayasu arteritis (TA)
sa
TA
extentb
Procedures required for disease recurrence or
progression
V Femorofemoral, profunda–popliteal BYP;
renal graft angioplasty  stent
V Aortoiliac, aortorenal, splenorenal BYP
V Contralateral aortorenal BYP, aortorenal
graft revision
V Femoral graft revision; aorto-SMA BYP,
femororenal BYP
IV Contralateral renal aortorenal BYP
d V Aortorenal, aortobicarotid BYP
V Carotid–subclavian BYP
V Asc aortic replacement; aortorenal,
aortocarotid BYP
V Aortorenal BYP
III Aortoiliac, aortorenal, carotid–carotid
BYP; asc aortic replacement
V Carotid endarterectomy, aortorenal BYP
IV Contralateral renal angioplasty
I Revision aortocarotid, femoral–axillary
BYP; asc aortic replacement
IV Renal graft angioplasty, iliac angioplasty 
stent
I Redo aortobicarotid BYP
III Exploration of para-anastomotic
pseudoaneurysm at distal anastomosis
ethotrexate; Pred, prednisone; SMA, superior mesenteric artery.
ex procedure.
al Conference Classification of TA.on o
cation
Pred
/Pre
isone
Pred
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TX, mtenoses demonstrated intimal hyperplasia.
t
t
M
l
o
t
p
p
s
t
e
t
h
C
b
t
s
c
t
p
e
b
a
p
u
v
g
U
T
b
t
h
p
F
w
p
m
JOURNAL OF VASCULAR SURGERY
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required 34 vascular procedures, including renal proce-
dures in 12, extremity in 8, cerebrovascular in 8, aortic
reconstructions in 6 (Tables II and III). The Tokyo Inter-
national Conference Classification of TA did not change for
any patients with disease progression. In other words,
disease progression only occurred in previously asymptom-
atic vascular beds with known lesions seen on the initial
aortogram.
The mean time from the initial revascularization proce-
dure to the subsequent procedure was 5.8 1.1 years. For
disease progressionmanifested by restenosis or occlusion of
the original vascular bed, the mean time from the initial
procedure to reintervention was 6.9  1.9 years. For pro-
gression in a previously asymptomatic vascular bed, the
mean time between the initial and subsequent procedure
was 5.0  1.1 years.
Of the 16 patients with disease progression/recur-
rence, 7 (44%) were receiving combination therapy with
corticosteroid and immunosuppressive agents vs 9 (56%)
who were not. Concomitant treatment with methotrexate
was used in two patients, cyclophosphamide in one, and
azathioprine in another. Of the seven patients who were
taking combination corticosteroid and immunosuppressive
agents, disease progressed in another previously asymptom-
atic vascular bed in two, recurred in the initial revascular-
ization in two, or progressed in both vascular beds in three
patients.
Four patients (25%) experienced five postoperative
complications, including intra-abdominal bleeding requir-
ing re-exploration in two, and myocardial infarction, groin
lymphocele requiring operative ligation, and recurrent la-
ryngeal nerve palsy in one patient each. One operative
death occurred in a patient who initially underwent tho-
racic aortobiiliac bypass with Dacron for thoracic and infra-
renal aortic occlusion. She was monitored for 6 years and
then lost to follow-up. The patient was admitted 8 years
later at another institution and underwent an operation for
a ruptured pseudoaneurysm of an iliac anastomosis. She
died in the operating room of exsanguination. The cause of
the pseudoaneurysm is unknown.
Three of the 16 patients with disease progression died
during the follow-up period. One patient who underwent a
successful revascularization died of a transfusion reaction
14 years after the index procedure, one died of a cardiac
event, and one patient lost to follow-up died of an un-
known cause. The 1-year and 5-year actuarial survival was
94% and 94%, respectively, after the index procedure and
94% and 85% after remedial procedures (Fig 2).
DISCUSSION
Abundant evidence exists that direct surgical revascu-
larization has a positive effect on the symptomatic manifes-
tations of TA. A number of reports have demonstrated
satisfactory outcomes with acceptable mortality rates in the
management of TA-related cerebrovascular lesions,6,16
atypical aortic coarctation,9 aortic aneurysm,17 renal artery
stenosis,12,18 coronary artery lesions,1 and aortic regurgi- gation.19,20 Our own group has published two reports on
he benefits of revascularization for symptomatic TA.10-12
iyata et al7 analyzed the effect of surgical treatment on
ong-term survival in a series of 106 patients with TA. The
verall cumulative survival rate was 73.5% at 20 years, and
hey demonstrated a survival benefit for surgically treated
atients whomanifest a greater severity of disease (Ishikawa
rognostic classification stage 3).7 We have observed a
imilar survival benefit of surgical revascularization in pa-
ients who typically present late in the disease with severe
nd-organ dysfunction.
Although the fate of symptomatic lesions is clear and
heir management relatively well characterized, the natural
istory of asymptomatic lesions in TA is less well known.
ertainly, it is recognized that lesion progression can occur
ut to what degree is unknown. There is evidence to believe
hat asymptomatic vascular lesions with arteritic disease
een on initial angiogram can progress over time and be-
ome symptomatic, often requiring surgical revasculariza-
ion.5,21 It is unclear whether progression of disease is
rimarily due to TA-related inflammatory changes or ath-
rosclerosis. It is likely to be a combination of both. We
elieve that an initial systemic inflammatory insult to the
rterial tree of variable duration during the acute or early
hase of TA leads to fibrotic changes of the arterial wall and
ltimately determines the anatomic extent of disease.
Various classification systems describing the patterns of
ascular distribution of disease, which are based on angio-
raphic findings, have been developed by Ueno et al,22
eda et al,23 and the International Conferences of TA.14
hese characteristic lesions of the arterial tree progress and
ecome symptomatic at variable intervals during the pa-
ient’s lifetime.
A precise clinical predictor of disease activity in TA
as proven to be elusive—except in the early acute
hase—a phase that is rarely seen by the vascular sur-
ig 2. Kaplan-Meier survival estimates are shown for patients
ith disease progression where time 0 begins from date of remedial
rocedure. *Standard error 10%; No, Number of patients re-
aining. Data are presented with the standard error of the mean.eon. In the later chronic phase with fixed fibrotic,
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and C-reactive protein are poor indicators of disease
activity and progression.10 The ESR as a marker of active
disease has a sensitivity of 36% and specificity of 83%
when compared with pathologic evaluation of specimens
of surgically treated patients.21 Disease activity based on
clinical, radiologic, and pathologic features appears to be
more helpful but is a poor predictor of the need for later
graft revision or subsequent disease progression. The
unpredictable course of TA underscores the need for
aggressive graft surveillance after revascularization.
Little data are available on the late outcome and pro-
gression of TA in other vascular beds after the initial oper-
ation. Only Lagneau et al5 in a series of 33 patients treated
surgically for TA addresses this issue. In their report with a
4-year mean follow-up, two patients had symptomatic and
angiographic progression of disease that required surgical
intervention. In one patient who underwent an initial ne-
phrectomy, the disease progressed 3 years later with lesions
in both carotids and the left subclavian artery that required
revascularization. The other patient who initially did not
undergo an operation at diagnosis presented 3 years later
with symptomatic and angiographic progression of aortic
lesions that required an aortoaortic bypass.
In another series of 25 patients reported by Robbs et
al,6 one patient with type V disease who underwent thora-
coabdominal aortic replacement with bilateral renal artery
revascularization for aneurysm and refractory hypertension
had symptomatic progression at one year in a previously
ectatic ascending aorta. Disease progression was manifested
by new symptom onset only and occurred despite the
patient taking continuous steroid therapy in the interim.6
In our series, progression or recurrence of disease oc-
curred in 40% of patients over a mean follow-up of 6.4
years. All patients had new or recurrent symptomatic pro-
gression. In no patient did disease progression change the
original TA classification. This supports the progressive
nature of TA, even after surgical treatment, and emphasizes
the importance of lifelong follow-up in these patients. TA
patients who do require surgical interventionmay represent
a unique group with more extensive and progressive dis-
ease; in effect, this self-selects patients who will require
multiple revascularizations over their lifetime.
The role and effect of concomitant use of steroid or
immunosuppressive therapy, or both, to slow TA disease
progression after revascularization is an area of controversy.
One series of 42 patients with TA treated surgically for
occlusive disease showed no survival benefit over 10 years
by Kaplan-Meier estimates in the 22 patients (52%) who
were taking steroid therapy at the time of operation com-
pared with patients who were not.21 Moreover, the same
study found no difference in freedom from revision or
disease progression in all 42 patients when analyzed by the
presence or absence of long-term steroid therapy. These
findings are similar to our own experience: Disease progres-
sion or recurrence was as likely in patients receiving long-
term steroid/immunosuppressive agents after revascular-
ization (44%) as in those who were not.Unlike the large series reported from Japan and Mex-
co, patients presenting to our institution and others in the
nited States seldom demonstrate the constitutional symp-
oms of acute arteritis such as fever, malaise, arthralgias, or
yalgias.24,25 Instead, patients often present with a clini-
ally “burned out” arteritis that manifests as symptomatic
rterial insufficiency or aneurysm formation. This may ex-
lain why steroid/immunosuppressive treatment at the
ime of surgery and biomarkers of disease activity have not
een particularly useful at our institution in the timing of
urgery or limiting disease progression.
Given these limitations of medical therapy, we believe
hat the optimal use of steroid/immunosuppressive therapy
s to attenuate the intensity of the systemic inflammatory
nsult to arterial tree in the early acute phase of TA, and
hereby limit the overall extent of disease involvement.
ow much of a benefit this may provide over time and its
alue in later stages of the disease is uncertain and requires
uture longitudinal studies.
ONCLUSIONS
Disease progression and need for subsequent reinter-
ention in patients surgically treated for TA is a common
ccurrence in those who require revascularization for end-
rgan ischemia. This finding emphasizes the need for
lobal lifelong vascular surveillance of all patients who
ndergo surgical intervention for TA. The requirement of
urgical reintervention is associated with minimal operative
ortality and provides acceptable late survival. The benefi-
ial effect of therapy with steroid and immunosuppressive
gents on surgical outcome is questionable and requires
urther investigation.
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